UNSPSC 51271915: Benzocaine hydrochloride

This classification denotes an anesthetic agent with the molecular formula C9H11NO2.CLH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier OG625Z9LEO. Most nations, for tariff and trade purposes, schedule benzocaine hydrochloride under HS 29224995 and SITC 51465. As of Q4 2014, BENZOCAINE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Benzocaine hydrochloride bears US NLM identifiers UMLS ID C0887581 and NCI Concept Code C97306. SMILES: CCOC(=O)C1CCC(CC1)N.CL.

UNSPSC 51271915 Benzocaine hydrochloride, a Commodity code, covers active pharmaceutical ingredients and finished-dose medications that state and local health agencies, purchasing cooperatives, and institutional buyers procure through wholesaler networks and cooperative purchasing agreements. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) administers a multi-state pharmaceutical procurement framework that sources generic pharmaceuticals and over-the-counter products across participating state and local government facilities, including Oregon. State and local governments typically buy benzocaine hydrochloride and similar products either as active ingredients for institutional compounding or as finished topical anesthetics for clinics, emergency departments, and field medical services. Purchasing follows formal competitive processes structured around authorized distributor networks, pricing transparency, and FDA compliance certification. Issuing bodies include state health departments, cooperative purchasing alliances, hospital systems, and county health agencies that consolidate buys to achieve volume discounts and standardized supply chains across multiple jurisdictions.

MMCAP, administered by the Minnesota Department of Administration's Office of State Procurement, posted a Request for Proposal on January 20, 2026 (due March 26, 2026) to establish multiple contracts for generic multi-source pharmaceuticals and OTC products with participation from Minnesota, Oregon, and other member states. Vendors must supply products through three authorized wholesalers—AmerisourceBergen Drug Corporation (Cencora), Cardinal Health 110 and 112, and Morris & Dickson Co., LLC—and demonstrate current Good Manufacturing Practices (cGMP) and Drug Supply Chain Security Act (DSCSA) compliance. Products must be available in the marketplace by May 15, 2026, with resulting contracts effective July 1, 2026. Evaluation criteria weight price competitiveness at 75 percent, fixed pricing at 10 percent, and compliance with administrative fee format, EDI capability, and 3 percent administrative fee agreement at 5 percent each. Vendors must maintain minimum insurance of $5,000,000 commercial general liability per occurrence and accept performance penalties ranging from $200 to $1,500 per violation for reporting delays or onboarding failures. The contract term is two years for new vendors with optional extensions at MMCAP's discretion, while incumbent vendors' amendments extend through June 30, 2028.